Kalincik T; Horakova D; Spelman T; Jokubaitis V; Trojano M; Lugaresi A; Izquierdo G; Rózsa, Csilla; Grammond P; Alroughani R; Duquette P; Girard M; Pucci E; Lechner-Scott J; Slee M; Fernandez-Bolanos R; Grand'Maison F; Hupperts R; Verheul F; Hodgkinson S; Oreja-Guevara C; Spitaleri D; Barnett M; Terzi M; Bergamaschi R; McCombe P; Sanchez-Menoyo J; Simó, Magdolna; Csepany T; Rum G; Boz C; Havrdova E; Butzkueven H; on behalf of the MSBase Study Group
(2015)
OBJECTIVE: In patients suffering multiple sclerosis activity despite treatment with interferon beta or glatiramer acetate, clinicians often switch therapy to either natalizumab or fingolimod. However, no studies have ...